Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Serina Therapeutics (SER) Non-Current Deffered Revenue (2020)

Serina Therapeutics' Non-Current Deffered Revenue history spans 1 years, with the latest figure at $64000.0 for Q4 2020.

  • For Q4 2020, Non-Current Deffered Revenue changed N/A year-over-year to $64000.0; the TTM value through Dec 2020 reached $64000.0, changed N/A, while the annual FY2020 figure was $64000.0, N/A changed from the prior year.
  • Non-Current Deffered Revenue for Q4 2020 was $64000.0 at Serina Therapeutics.
  • Across five years, Non-Current Deffered Revenue topped out at $64000.0 in Q4 2020 and bottomed at $64000.0 in Q4 2020.